Skip to content

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

News

Read the latest news about our company.
To learn more about our research, visit our publications page.

See our publications

Year
Media Type
Search

July 9, 2024 | Press Release

Interius BioTherapeutics Receives HREC Approval and CTN Clearance from the TGA to Commence a Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies

July 9, 2024 | Media Coverage

BioSpace: Interius Gets Go-Ahead for Phase I Trial of In Vivo CAR-T Therapy in Australia

July 9, 2024 | Media Coverage

CGTLive: Interius BioTherapeutics In Vivo CAR Therapy INT2104 Cleared for Phase 1 Clinical Trial in B-cell Malignancies Australia

July 9, 2024 | Media Coverage

STAT News: A faster, simpler, cheaper cancer cell therapy is about to be tested in humans

April 23, 2024 | Press Release

Interius BioTherapeutics to Present In Vivo CAR Data in Oncology and Autoimmunity Programs at the American Society of Gene and Cell Therapy 27th Annual Meeting

June 21, 2023 | Press Release

Interius BioTherapeutics Highlights Strong Preclinical Data Supporting In Vivo Chimeric Antigen Receptor (CAR) Vector Evaluation in Clinic

«...2 345 6

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Platform
- Overview
- Publications and Presentations
Pipeline
- Overview
- Clinical Trials
About Us
Careers
News
Contact

Science

Platform
Pipeline
INT2104
INT2106
Publications
Clinical Trials

Company

About Us
Leadership
Board of Directors
Careers
Contact
News

Copyright © 2025 Interius BioTherapeutics, Inc. All Rights Reserved.
Interius^® is a registered trademark of Interius BioTherapeutics, Inc.

Accessibility
Cookies Notice
Privacy Notice
Terms of Use

Interius is now part of Kite, a Gilead Company.

We are singularly focused on achieving cures with cell therapy.

Learn More About Kite